Deep Bio said Friday that its deep learning-based prostate cancer pathology image analysis software, DeepDx-Prostate Pro, was selected as the Public Procurement Service's (PPS) innovative prototype (Fast Track II) in the bio-health area.To improve public services and innovate technology, the PPS des
Korea saw a trade surplus in vaccines for humans for the first time in the first half of this year, raising expectations for further growth of the vaccine industry.According to a report on exports and imports of human vaccines and diagnostic agents, published by the Korea Biotechnology Industry Orga
GenScript ProBio signed a memorandum of understanding with DAAN Bio Therapeutics to cooperate to discover and develop innovative drugs on Thursday.Through this MOU, GenScript ProBio and DAAN agreed to strengthen their cooperation, specifically in the cell and gene therapy (CGT) and biologics field.T
The U.S. FDA put off a decision on whether to approve tislelizumab, anti-PD-1 immunotherapy developed by BeiGene and Novartis, due to Covid-19-related travel restrictions.BeiGene, the Chinese pharmaceutical firm, said on Thursday that the FDA deferred a decision on approval for tislelizumab as a sec
The Research Investment for Global Health Technology Fund (RIGHT Fund) committed an additional 4 billion won ($3 million) to support four newly selected research projects concerning infectious diseases in the first half of 2022.The four recipients of the additional grants are CHA Vaccine Institute,
On Thursday, quarantine officials detected the first case of BA.2.75, dubbed “Centarus,” the most contagious Omicron subvariant with greater immune-avoidance properties than BA.5.BA.2.75, first sequenced in India in May, has been found in about 10 countries, including the U.S., Australia, and German
Wells Bio said Thursday that it has obtained an export license for its new pneumonia molecular diagnostic kit, “careGENE Pneumonia detection kit.”The kit is an in vitro diagnostic medical device that helps diagnose pneumonia infection. It detects the nucleic acid of pneumonia in sputum and nasophary
GC Biopharma said Thursday it has received an investigational new drug (IND) approval from the Ministry of Food and Drug Safety for the researcher-led administration of Neulapeg on the same day after anticancer chemotherapy.The company said it is the first such clinical trial to be held in Korea.Neu
Study results to be presented at the WCLC in August will influence the direction of Yuhan Corp's Leclaza (Ingredient: lazertinib), the nation's 31st novel drug for NSCLC, and the corporate's value, a local analyst said."Yuhan will present three abstracts concerning its non-small cell lung cancer (NS
The clinical trial result of HLB’s targeted anticancer medicine rivoceranib will be presented at the 2022 International Association for the Study of Lung Cancer (IASLC 2022), the company said Thursday.IASLC, the world’s largest symposium for lung cancer and other thoracic malignancy, will be held in
Despite Korean diagnostic companies pinning high hopes on monkeypox as a new growth engine after their big success during the Covid-19 pandemic, industry watchers are expressing doubt that their expectations would turn into a reality.The number of monkeypox infections has rapidly increased worldwide
The Seoul National University Hospital (SNUH) said Thursday that it launched a full-fledged study to develop digital treatments for abnormal behaviors and problems linked to autism spectrum disorder.Under the auspices of the Ministry of Science and ICT, the hospital will push the project using about
Fears of Covid-19 resurgence are spreading, but SK Bioscience has yet to apply for a lot release of SKYCovione, the first homegrown Covid-19 vaccine.On Wednesday, SK Bioscience confirmed SKYCovicone’s immune response to the Omicron variant BA.1 in extended phase 1 and 2 trials.The company gave two d
SK Biopharmaceuticals said it signed a $62 million licensing agreement to commercialize cenobamate (brand name: Xcopri), an anti-epileptic treatment, in Latin America.In a public filing on Thursday, the company said it licensed out cenobamate to Eurofarma Laboratorios SA for the commercialization of
MSD’s anti-PD-1 therapy Keytuda (pembrolizumab) won expanded indication to be used as neoadjuvant therapy in combination with chemotherapy before surgery in patients with triple-negative breast cancer (TNBC) and then continued as a single agent after surgery.This indication allows Keytruda to treat
Next-generation ALK inhibitors such as Alecensa (alectinib) and Lorviqua (lorlatinib) showed high activity in relapsed and refractory anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL), signaling their potential as a treatment option, a study said.No standard therapies exist for
GemVax & Kael, an immunotherapy drug developer, said on Wednesday that the company had secured safety in the non-clinical toxicity trials of GV1001, the company’s 16-amino-acid peptide immunotherapy drug for pancreatic cancer.New substances generally require various strict conditions to be met to be
The government has decided not to implement strict distancing rules, although new virus cases herald the advent of another Covid-19 wave.Instead, it will expand the targets of second booster shots to people in their 50s and those aged 18 and older with underlying conditions, quarantine officials sai
Bridge Biotherapeutics will present the phase 1 clinical trial’s result of BBT-176, the fourth-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) drug, at the World Conference on Lung Cancer (WCLC) in Vienna next month.The conference organizers made public the abstract
JW Group said Wednesday that it signed an agreement with ARCH Venture Partners, a U.S. venture capital, to promote open innovation strategies with global bio companies.Under the accord, JW Group will receive ARCH Technical Service (ATS) programs, which provide promising biotech and technical informa